韩国分离的需氧菌和厌氧菌临床株的体外比较活性：替唑烷（DA-7157）。
Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.
机构信息
Department of Clinical Laboratory Science, Dong-eui University, Busan, South Korea.
出版信息
Antimicrob Agents Chemother. 2010 Dec;54(12):5381-6. doi: 10.1128/AAC.00728-10. Epub 2010 Sep 13.
Abstract
Resistance of Gram-positive pathogens to first-line antimicrobial agents has been increasing in many parts of the world. We compared the in vitro activities of torezolid with those of other antimicrobial agents, including linezolid, against clinical isolates of major aerobic and anaerobic bacteria. Torezolid had an MIC(90) of ≤0.5 μg/ml for the Gram-positive bacterial isolates tested and was more potent than either linezolid or vancomycin.
摘要
革兰阳性病原体对抗一线抗菌药物的耐药性在世界许多地区都在不断增加。我们比较了替唑烷与其他抗菌药物（包括利奈唑胺）对主要需氧和厌氧细菌临床分离株的体外活性。替唑烷对所测试的革兰阳性细菌分离株的 MIC(90)≤0.5μg/ml，比利奈唑胺或万古霉素的活性更强。
相似文献
1
Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.
Antimicrob Agents Chemother. 2010 Dec;54(12):5381-6. doi: 10.1128/AAC.00728-10. Epub 2010 Sep 13.
2
In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. doi: 10.1128/AAC.48.1.352-357.2004.
3
Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
Antimicrob Agents Chemother. 2010 May;54(5):2212-5. doi: 10.1128/AAC.01653-09. Epub 2010 Feb 22.
4
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).
Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.
5
Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
J Chemother. 2003 Apr;15(2):113-7. doi: 10.1179/joc.2003.15.2.113.
6
Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
Antimicrob Agents Chemother. 2010 May;54(5):2063-9. doi: 10.1128/AAC.01569-09. Epub 2010 Mar 15.
7
In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.
J Antimicrob Chemother. 2012 Jan;67(1):167-9. doi: 10.1093/jac/dkr403. Epub 2011 Sep 27.
8
Activity of linezolid against anaerobic bacteria.
Int J Antimicrob Agents. 2003 Jul;22(1):28-34. doi: 10.1016/s0924-8579(03)00087-6.
9
Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.
Eur J Med Chem. 2011 Apr;46(4):1027-39. doi: 10.1016/j.ejmech.2011.01.014. Epub 2011 Jan 18.
10
Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines.
J Antimicrob Chemother. 2009 Nov;64(5):1035-43. doi: 10.1093/jac/dkp267. Epub 2009 Sep 16.
引用本文的文献
1
The antimicrobial activity of linezolid against unconventional pathogens.
PeerJ. 2025 Feb 12;13:e18825. doi: 10.7717/peerj.18825. eCollection 2025.
2
Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis.
Ann Clin Microbiol Antimicrob. 2022 Aug 17;21(1):37. doi: 10.1186/s12941-022-00529-z.
3
Pharmacokinetics and Pharmacodynamics of Tedizolid.
Clin Pharmacokinet. 2022 Apr;61(4):489-503. doi: 10.1007/s40262-021-01099-7. Epub 2022 Feb 7.
4
In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid.
Braz J Infect Dis. 2017 Sep-Oct;21(5):493-499. doi: 10.1016/j.bjid.2017.03.010. Epub 2017 Apr 19.
5
Recent Advances in the Rational Design and Optimization of Antibacterial Agents.
Medchemcomm. 2016 Sep 1;7(9):1694-1715. doi: 10.1039/C6MD00232C. Epub 2016 Jul 7.
6
In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study.
Ann Lab Med. 2015 Sep;35(5):523-30. doi: 10.3343/alm.2015.35.5.523.
7
Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7.
8
Tedizolid phosphate.
Hosp Pharm. 2014 Nov;49(10):961-71. doi: 10.1310/hpj4910-961.
9
Lack of neuropathological changes in rats administered tedizolid phosphate for nine months.
Antimicrob Agents Chemother. 2015 Jan;59(1):475-81. doi: 10.1128/AAC.03950-14. Epub 2014 Nov 10.
10
Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.
Antimicrob Agents Chemother. 2015 Jan;59(1):178-85. doi: 10.1128/AAC.03684-14. Epub 2014 Oct 20.
本文引用的文献
1
Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
Antimicrob Agents Chemother. 2010 May;54(5):2063-9. doi: 10.1128/AAC.01569-09. Epub 2010 Mar 15.
2
Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.
3
In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.
Antimicrob Agents Chemother. 2008 Dec;52(12):4442-7. doi: 10.1128/AAC.00859-08. Epub 2008 Oct 6.
4
High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.
Yonsei Med J. 2006 Oct 31;47(5):634-45. doi: 10.3349/ymj.2006.47.5.634.
5
Mechanism of action of the oxazolidinone antibacterial agents.
Expert Opin Investig Drugs. 1999 Aug;8(8):1195-202. doi: 10.1517/13543784.8.8.1195.
6
Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002).
J Clin Microbiol. 2005 Jan;43(1):462-3. doi: 10.1128/JCM.43.1.462-463.2005.
7
In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. doi: 10.1128/AAC.48.1.352-357.2004.
8
In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Antimicrob Agents Chemother. 2003 Jun;47(6):1902-6. doi: 10.1128/AAC.47.6.1902-1906.2003.
9
In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Antimicrob Agents Chemother. 2002 Nov;46(11):3484-9. doi: 10.1128/AAC.46.11.3484-3489.2002.
10
In vitro activity of the new oxazolidinone AZD2563 against Enterococci.
Antimicrob Agents Chemother. 2002 Oct;46(10):3273-5. doi: 10.1128/AAC.46.10.3273-3275.2002.
Zotero 插件